What is IGF-1 LR3? IGF-1 LR3 (Long R3 IGF-1) is a laboratory-engineered analog of native insulin-like growth factor 1, a 70-amino-acid signaling protein that occupies a central place in growth and metabolic biology. The “LR3” designation reflects two deliberate modifications to the parent molecule that change how it interacts with the proteins that normally regulate IGF-1 in the body. This overview summarizes the structure, mechanism, and research context of IGF-1 LR3 as a subject of scientific study, drawing on peer-reviewed and preclinical literature indexed in PubMed.
Native IGF-1: the starting point
Insulin-like growth factor 1 is an endogenous peptide structurally related to insulin. It signals primarily through the type 1 IGF receptor (IGF-1R) and is closely involved in cellular proliferation and differentiation across many tissue types. In circulation, native IGF-1 rarely travels alone: the large majority is bound to a family of insulin-like growth factor binding proteins (IGFBPs), particularly IGFBP-3. These binding proteins act as carriers and regulators, extending the molecule’s half-life while also sequestering it and limiting how much is free to engage the receptor at any moment. Understanding this binding-protein system is essential to understanding why an analog like IGF-1 LR3 was designed at all.
What is IGF-1 LR3 at the molecular level
IGF-1 LR3 differs from the native peptide in two engineered ways. First, the arginine-3 substitution (“R3”) replaces the glutamic acid at position 3 with arginine. Second, a 13-amino-acid extension peptide is added to the N-terminus (the “Long” component). Together these changes markedly reduce the molecule’s affinity for the IGFBPs while leaving its ability to bind the IGF-1 receptor largely intact. Cascieri and Bayne, reviewing site-directed mutagenesis work on IGF-I analogs, described how distinct structural domains govern receptor binding versus binding-protein binding, and how analogs can be constructed to bind the receptor selectively while binding IGFBPs poorly (PMID 7522208). Grimes and Hammond, working in cultured ovarian granulosa cells, characterized Long R3-IGF-I as an analog with “very low affinity for IGFBPs and only slightly reduced affinity for the IGF-I (type I) receptor” (PMID 1379161).
Why the modifications matter in vitro
Because IGFBPs normally restrain free IGF-1, an analog that evades them behaves differently in laboratory systems. In the granulosa-cell work above, Long R3-IGF-I showed significantly greater potency than native IGF-I in stimulating binding-protein production, a difference the authors attributed directly to its reduced sequestration by IGFBPs (PMID 1379161). Studies of murine bone-marrow-derived macrophage precursors similarly used Long R3 IGF-1 alongside native IGF-1 and des(1-3)-IGF-1 as tools to probe the modulating role of binding proteins in proliferation and differentiation (PMID 9867252). In these contexts the analog functions as a research reagent for dissecting IGF signaling rather than as an endpoint in itself.
Protein engineering and stability research
IGF-1 LR3 has also been a scaffold for further protein-engineering investigation. Bryant and colleagues used site-directed mutagenesis to build pepsin-resistant single-point variants of Long-R3-IGF-I, mapping the peptide bonds most susceptible to enzymatic cleavage and identifying substitutions that improved stability while retaining growth-promoting activity in their assays (PMID 8919033). This line of work illustrates how the analog serves as a platform for studying structure-stability relationships in the broader IGF/insulin peptide family. More recent structural studies of engineered insulin analogs that bind both the insulin and IGF-1 receptors continue to illuminate how small changes at defined sites reshape receptor specificity across this hormone family (PMID 30213860).
Preclinical animal-model findings
Several preclinical studies have administered Long R3 IGF-1 in livestock models, with results that underscore how context-dependent IGF signaling is. In beef heifers on a restricted diet, an intravenous infusion of Long(R3)-IGF-1 tended to conserve whole-body and muscle protein and sharply reduced circulating amino acids and glucose in the treated group (PMID 10370861). By contrast, in finisher pigs a four-day infusion of Long[R3]-IGF-I decreased average daily gain, feed intake, and plasma IGFBP-3, IGF-I, and insulin concentrations, with the authors noting that IGFBP-evading analogs that stimulate growth in the rat can instead inhibit growth in the pig (PMID 9488001). These divergent outcomes highlight that findings in one species or model do not generalize, and that the evidence base remains preclinical and heterogeneous.
Interpreting the research landscape
The published literature on IGF-1 LR3 is concentrated in in-vitro systems and animal models from the 1990s and early 2000s, much of it using the analog as an experimental probe of the IGF/IGFBP axis rather than as a therapeutic candidate in its own right. There is no body of controlled human clinical trial evidence establishing effects in people, and the preclinical results that do exist are mixed and species-dependent. Anyone reviewing this compound for scientific purposes should read the primary sources directly, weigh the model system used, and treat mechanistic in-vitro potency as distinct from any whole-organism outcome.
References
- Cascieri MA, Bayne ML. Analysis of the interaction of insulin-like growth factor I (IGF-I) analogs with the IGF-I receptor and IGF-binding proteins. Horm Res. 1994. DOI: 10.1159/000183965 (PMID 7522208)
- Grimes RW, Hammond JM. Insulin and insulin-like growth factors (IGFs) stimulate production of IGF-binding proteins by ovarian granulosa cells. Endocrinology. 1992. DOI: 10.1210/endo.131.2.1379161 (PMID 1379161)
- Bryant KJ, Read LC, Forsberg G, Wallace JC. Design and characterisation of long-R3-insulin-like growth factor-I muteins which show resistance to pepsin digestion. Growth Factors. 1996. DOI: 10.3109/08977199609003227 (PMID 8919033)
- Dunaiski V, Dunshea FR, Walton PE, Goddard C. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol. 1997. DOI: 10.1677/joe.0.1550559 (PMID 9488001)
- Hill RA, Hunter RA, Lindsay DB, Owens PC. Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. Domest Anim Endocrinol. 1999. DOI: 10.1016/s0739-7240(99)00015-6 (PMID 10370861)
- Long E, Huynh HT, Zhao X. Involvement of insulin-like growth factor-1 and its binding proteins in proliferation and differentiation of murine bone marrow-derived macrophage precursors. Endocrine. 1998. DOI: 10.1385/ENDO:9:2:185 (PMID 9867252)
- Chrudinová M, Žáková L, Marek A, et al. A versatile insulin analog with high potency for both insulin and insulin-like growth factor 1 receptors: Structural implications for receptor binding. J Biol Chem. 2018. DOI: 10.1074/jbc.RA118.004852 (PMID 30213860)
Citations retrieved from PubMed. Please consult the original articles via the linked DOIs for full methods and context.
Research Use Only. IGF-1 LR3 is a research compound intended solely for laboratory and scientific research purposes. It is not a drug, dietary supplement, or medical product, and it is not intended for human or animal consumption or for any diagnostic or therapeutic use. Nothing in this educational article constitutes medical advice or a claim of safety or efficacy. Content is provided for informational and educational purposes only.